Prothena Corporation plc
Industry
- Pharmaceuticals
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
Other Names/Subsidiaries
- Neotope Biosciences Limited
Latest on Prothena Corporation plc
Roche is taking a leap of faith with its Parkinson’s disease candidate, prasinezumab, and will move the potential first-in-class into Phase III despite it falling short in two mid-stage trials. The Sw
Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the
The Parkinson’s field is littered with clinical failures and another candidate, UCB’s minzasolmin, is the latest to fall in the quest for a disease modifying treatment. The Belgium-based group has i
S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai